Literature DB >> 7016643

Adrenergic influence on glucocounterregulation in man.

U Lilavivat, R G Brodows, R G Campbell.   

Abstract

To investigate the adrenergic role in glucocounterregulatory mechanisms, single-blind randomised studies were performed in 7 normal males during severe insulin-induced hypoglycaemia with or without adrenergic blockade. Intravenous phentolamine administration (5 mg stat and 0.5 mg/min) did not interfere with the restoration of euglycaemia from hypoglycaemia. However, recovery of blood glucose in the presence of propranolol (3 mg/3 min and 0.8 mg/min) was retarded when compared with control studies (mean plasma glucose levels +/- SEM , 50 +/- 6 mg/dl versus 66 +/- 4 mg/dl at 120 min after insulin administration) despite appropriate glucagon, epinephrine, cortisol, and growth hormone responses. Plasma norepinephrine response was unaffected by propranolol but augmented threefold by phentolamine. Increases in plasma lactate, pyruvate and non-esterified fatty acids were blunted with propranolol while rebound non-esterified fatty acid was observed with phentolamine infusion. These data suggest that complete recovery of blood glucose from sever hypoglycaemia requires full sympathetic nervous system activity despite the integrity of other counterregulatory mechanisms.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7016643     DOI: 10.1007/bf00253412

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  39 in total

1.  Adrenaline excretion during resting conditions and after insulin in adrenalectomized human subjects.

Authors:  U von EULER; D IKKOS; R LUFT
Journal:  Acta Endocrinol (Copenh)       Date:  1961-11

2.  Comparison of atenolol and propranolol during insulin-induced hypoglycaemia.

Authors:  S P Deacon; D Barnett
Journal:  Br Med J       Date:  1976-07-31

Review 3.  The glucose-alanine cycle.

Authors:  P Felig
Journal:  Metabolism       Date:  1973-02       Impact factor: 8.694

4.  A simplified radiometric assay for plasma norepinephrine and epinephrine.

Authors:  P G Passon; J D Peuler
Journal:  Anal Biochem       Date:  1973-02       Impact factor: 3.365

Review 5.  The hormonal control of hepatic gluconeogenesis.

Authors:  J H Exton; L E Mallette; L S Jefferson; E H Wong; N Friedmann; T B Miller; C R Park
Journal:  Recent Prog Horm Res       Date:  1970

6.  Effects of propranolol on the hormonal and metabolic responses to insulin-induced hypoglycaemia.

Authors:  E A Abramson; R A Arky; K A Woeber
Journal:  Lancet       Date:  1966-12-24       Impact factor: 79.321

7.  Blood glucose regulates the effects of insulin and counterregulatory hormones on glucose production in vivo.

Authors:  L Saccà; P E Cryer; R S Sherwin
Journal:  Diabetes       Date:  1979-06       Impact factor: 9.461

8.  Effect of sotalol (MJ 1999) and propranolol on insulin-induced hypoglycemia in the rat.

Authors:  J H Brown; D A Riggilo
Journal:  Proc Soc Exp Biol Med       Date:  1968-04

9.  Neural control of counter-regulatory events during glucopenia in man.

Authors:  R G Brodows; F X Pi-Sunyer; R G Campbell
Journal:  J Clin Invest       Date:  1973-08       Impact factor: 14.808

10.  The role of cortisol and growth hormone in the counter-regulation of insulin-induced hypoglycemia.

Authors:  J M Feldman; J W Plonk; C H Bivens
Journal:  Horm Metab Res       Date:  1975-09       Impact factor: 2.936

View more
  2 in total

1.  Propranolol diminishes extremity blood flow in burned patients.

Authors:  D C Gore; D Honeycutt; F Jahoor; R E Barrow; R R Wolfe; D N Herndon
Journal:  Ann Surg       Date:  1991-06       Impact factor: 12.969

2.  Plasma Epinephrine Contributes to the Development of Experimental Hypoglycemia-Associated Autonomic Failure.

Authors:  Eric Lontchi-Yimagou; Sandra Aleksic; Raphael Hulkower; Rebekah Gospin; Akankasha Goyal; Bryan Kuo; William G Mitchell; Jee Young You; Laxmi Upadhyay; Michelle Carey; Oana A Sandu; Ilan Gabriely; Harry Shamoon; Meredith Hawkins
Journal:  J Clin Endocrinol Metab       Date:  2020-11-01       Impact factor: 5.958

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.